Cizzle Biotechnology Holdings Plc (CIZ.L) Stock
Cizzle Biotechnology Holdings Plc

Company profile
Cizzle Biotechnology Holdings reports about 5 full-time employees.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Cizzle Biotechnology Holdings Plc
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Leadership
- Allan John Syms — Executive Chairman, 69
- Dawn Coverley — Founder, Chief Scientific Officer & Executive Director, 60
- Nigel R. Lee — Finance Director & Executive Director, 64
What companies are similar to Cizzle Biotechnology Holdings?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Elekta AB (publ) (0O5H.IL), Creo Medical Group PLC (CREO.L), Inspiration Healthcare Group plc (IHC.L), TruSpine Technologies Plc (TSP.AQ).
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Cizzle Biotechnology Holdings Plc (CIZ.L)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/CIZ.L